Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of intravenous ibandronic acid for analgesic induction in multiple myeloma
2006-006111-77Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibandronic acid in multiple myeloma (MM), sponsored by Roche. Primary endpoints: Safety and Analgesic efficacy by day 8. Started Feb 2007; status: completed.
02
Drugs
ibandronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-006111-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006111-77.